Rheumatoid Arthritis Treatment Market size was valued at USD 33.69 billion in 2023 and is likely to reach USD 72.74 billion by the end of 2036, registering around 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of rheumatoid arthritis treatment is assessed at USD 35.33 billion.
The market growth can be attributed to the growing prevalence of rheumatoid arthritis and musculoskeletal conditions, such as, Carpal Tunnel syndrome, globally. Rheumatoid arthritis is an autoimmune disease and a chronic inflammatory disorder that affects many joints, including those in the hands and feet. It can be challenging to diagnose early because the early signs and symptoms mimic various other diseases. Currently, there is no treatment for rheumatoid arthritis; however, certain drugs are prescribed to efficiently control the conditions of rheumatoid arthritis, which include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), corticosteroids, and uric acid drugs. Furthermore, the market is projected to grow owing to the favourable government reimbursement policies, and increasing healthcare expenditure. The changing lifestyles, rising pollution levels and, changes in metabolic activities due to chronic diseases, such as, diabetes are fuelling the prevalence of rheumatoid arthritis which is projected to boost the market growth. Moreover, the increasing number of collaborations and partnerships between pharmaceutical companies, combined with the growing R&D expenditure for the treatment and novel therapies of rheumatoid arthritis is expected to drive market growth. Additionally, the rising awareness about this condition and increasing healthcare infrastructure will lead to market growth in the forecast period.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.1% |
|
Base Year Market Size (2023) |
USD 33.69 billion |
|
Forecast Year Market Size (2036) |
USD 72.74 billion |
|
Regional Scope |
|
The market is segmented based on drug class into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. The disease-modifying anti-rheumatic drugs (DMARDs) segment is anticipated to grab the most significant share by the end of 2021 on account of the increase in the adoption of DMARDs as a first-line treatment for rheumatoid arthritis. These drugs control the progression of rheumatoid arthritis, and provide quick relief as compared to other medications.
Based on end-user, the retail pharmacy segment in the rheumatoid arthritis treatment market is projected to grow with a notable CAGR over the forecast period. The segment's growth can be attributed to the easy access of drugs in retail pharmacy for the general population. Moreover, the trend for taking online orders by retail pharmacies increases and is estimated to result in segment growth. Additionally, online pharmacy is also expected to grow during the forecast period due to the growing internet penetration and adoption of e-commerce services.
Our in-depth analysis of the global market includes the following segments
|
By Drug Class |
|
|
By Distribution channel |
|
Regionally, the global rheumatoid arthritis treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is anticipated to hold largest revenue share by 2036, owing to increased research and development expenditure for rheumatoid arthritis by governmental agencies, and improving healthcare infrastructure in the region. The percentage of rheumatoid arthritis prevalence in APAC seems to be less than that in Europe and North America, the total number of rheumatoid arthritis patients in Asia is approximately 10 million, which poses a significant burden on the developing societies.
North America Market Analysis
Furthermore, the rheumatoid arthritis treatment market in North America is evaluated to occupy the largest share in terms of revenue, in 2021 owing to the presence of various reimbursement policies, increasing awareness about the disease via support groups, and increasing adoption of physiotherapy. Moreover, the presence of major companies in the region and growing investment in therapies and novel drugs to treat rheumatoid arthritis, along with the increasing number of drugs in the pipeline and the growing clinical trials are expected to boost the market growth in the region, especially in the United States.
February 2021: Pfizer Inc. and Imcyse, a Belgium-based clinical-stage biopharmaceutical company, announced a research collaboration and license agreement for the potential treatment of rheumatoid arthritis (RA) via Imcyse’s rheumatoid arthritis program based on its Imotope technology.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?